Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Malin Sund

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7516-9543; OpenAlex author ID A5042856380. Sources: OpenAlex.

Their work

Papers
64 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
117
Papers, trials and grants by year

2011: 2 papers · 2012: 6 papers · 2013: 6 papers · 2014: 4 papers · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 3 papers · 2019: 7 papers · 2020: 6 papers · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 4 papers · 2025: 4 papers · 2026: 5 papers

Papers 50 of 64

  1. Diabetes Among Finnish Pancreatic Cancer Patients: Prevalence, Time Interval Between Diabetes and Cancer Diagnosis, and Overall Survival. Co-author DOI 10.1002/cam4.72380↗
  2. Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000547820↗
  3. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20191-5↗
  4. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20304-0↗
  5. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20312-0↗
  6. High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review. Co-author DOI 10.1016/j.pan.2024.11.010↗
  7. The prognostic significance of MMP-8 tissue Immunoexpression in pancreatic ductal adenocarcinoma after neoadjuvant therapy. Last author DOI 10.1038/s41598-025-10538-5↗
  8. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Co-author DOI 10.3390/cancers17142275↗
  9. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuv… Co-author DOI 10.3892/ol.2024.14845↗
  10. Can our experience with surveillance for inherited pancreatic cancer help to identify early pancreatic cancer in the general population? Last author DOI 10.1007/s10689-024-00363-6↗
  11. Multi-omics profiling to identify early plasma biomarkers in pre-diagnostic pancreatic ductal adenocarcinoma: a nested case-control study. Last author DOI 10.1016/j.tranon.2024.102059↗
  12. The Prognostic Significance of Collagen VI in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002360↗
  13. Metabolomics for early pancreatic cancer detection in plasma samples from a Swedish prospective population-based biobank. Last author DOI 10.21037/jgo-23-930↗
  14. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  15. Plasma concentrations of persistent organic pollutants and pancreatic cancer risk. Co-author DOI 10.1093/ije/dyab115↗
  16. Matrix Metalloproteinase 8 Expression in a Tumour Predicts a Favourable Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms23063314↗
  17. A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/ijms232112969↗
  18. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  19. Hyperglycemia as a risk factor in pancreatic cancer: A nested case-control study using prediagnostic blood glucose levels. Co-author DOI 10.1016/j.pan.2021.05.008↗
  20. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures. Co-author DOI 10.1158/1055-9965.epi-21-0169↗
  21. Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples. Last author DOI 10.3390/cancers13215321↗
  22. Incorporating multiple sets of eQTL weights into gene-by-environment interaction analysis identifies novel susceptibility loci for pancreatic cancer. Co-author DOI 10.1002/gepi.22348↗
  23. Consumption of nuts and seeds and pancreatic ductal adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition. Co-author DOI 10.1002/ijc.32415↗
  24. Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. Co-author DOI 10.1007/s10654-019-00559-6↗
  25. Mesoscopic 3D imaging of pancreatic cancer and Langerhans islets based on tissue autofluorescence. Co-author DOI 10.1038/s41598-020-74616-6↗
  26. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  27. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort. Co-author DOI 10.1158/1055-9965.epi-19-0868↗
  28. Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer. Last author DOI 10.1002/cjp2.122↗
  29. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Co-author DOI 10.1002/ijc.31900↗
  30. Methodological issues in a prospective study on plasma concentrations of persistent organic pollutants and pancreatic cancer risk within the EPIC cohort. Co-author DOI 10.1016/j.envres.2018.11.027↗
  31. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  32. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  33. Socioeconomic Effect of Education on Pancreatic Cancer Risk in Western Europe: An Update on the EPIC Cohorts Study. Co-author DOI 10.1158/1055-9965.epi-18-1153↗
  34. miRFA: an automated pipeline for microRNA functional analysis with correlation support from TCGA and TCPA expression data in pancreatic cancer. Last author DOI 10.1186/s12859-019-2974-3↗
  35. Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study. Co-author DOI 10.1002/ijc.31367↗
  36. VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. Co-author DOI 10.1002/path.5141↗
  37. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000002124↗
  38. Use of moist oral snuff (snus) and pancreatic cancer: Pooled analysis of nine prospective observational studies. Co-author DOI 10.1002/ijc.30773↗
  39. Mediterranean diet and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Co-author DOI 10.1038/bjc.2017.14↗
  40. Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. Co-author DOI 10.1002/ijc.30190↗
  41. Prognostic and predictive markers in pancreatic adenocarcinoma. First author DOI 10.1016/j.dld.2015.11.001↗
  42. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Co-author DOI 10.1159/000453257↗
  43. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  44. Plasma carotenoids, vitamin C, retinol and tocopherols levels and pancreatic cancer risk within the European Prospective Investigation into Cancer and Nutritio… Co-author DOI 10.1002/ijc.29175↗
  45. New Advances in the Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.1159/000439523↗
  46. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. Last author DOI 10.3233/cbm-140430↗
  47. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  48. Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS d… Co-author DOI 10.1093/carcin/bgu010↗
  49. Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. Co-author DOI 10.1158/1055-9965.epi-13-0437-t↗
  50. Leukocyte telomere length in relation to pancreatic cancer risk: a prospective study. Co-author DOI 10.1158/1055-9965.epi-14-0247↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Öhlund · 15 shared papers, 2013–2026 · strength 2.40
  2. Oskar Franklin · 16 shared papers, 2013–2026 · strength 2.39
  3. Hanna E. Seppänen · 7 shared papers, 2022–2026 · strength 1.74
  4. Caj H. Haglund · 7 shared papers, 2022–2026 · strength 1.74
  5. Ella Kesti · 5 shared papers, 2024–2026 · strength 1.25
  6. Nils O. Elander · 4 shared papers, 2025–2026 · strength 1.00
  7. Hakon Blomstrand · 4 shared papers, 2025–2026 · strength 1.00
  8. Emmy Borgmästars · 5 shared papers, 2019–2024 · strength 0.92
  9. Eric J. Duell · 25 shared papers, 2011–2020 · strength 0.84
  10. Rudolf Kaaks · 19 shared papers, 2011–2025 · strength 0.79
  11. Verena Andrea Katzke · 13 shared papers, 2013–2025 · strength 0.78
  12. Jun Yoshino · 3 shared papers, 2026 · strength 0.77
  13. Asif Halimi · 3 shared papers, 2026 · strength 0.77
  14. Elio Ríboli · 21 shared papers, 2011–2020 · strength 0.66
  15. Esther Molina‐Montes · 17 shared papers, 2011–2025 · strength 0.60
  16. H. Bas Bueno-de-Mesquita · 20 shared papers, 2011–2020 · strength 0.59
  17. Sara Jacobson · 3 shared papers, 2021–2024 · strength 0.54
  18. Matthias J. Löhr · 2 shared papers, 2024–2025 · strength 0.50
  19. Federico Canzian · 7 shared papers, 2012–2025 · strength 0.45
  20. Mirjami Kaasinen · 2 shared papers, 2022–2025 · strength 0.42
  21. Vinciane Rebours · 6 shared papers, 2018–2021 · strength 0.39
  22. Guri Skeie · 11 shared papers, 2011–2020 · strength 0.39
  23. Seppänen Hanna · 1 shared paper, 2026 · strength 0.39
  24. Panu Aaltonen · 1 shared paper, 2026 · strength 0.39
  25. Suitiala Roosa · 1 shared paper, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.